Nicholas Hornstein, Assistant Professor of Medical Oncology at Northwell Health, posted on X:
“Something new in BRAF V600E mCRC!
encorafenib (enco) + cetuximab (cet) + FOLFOX.
Nice increase in ORR (61% vs 40%)
~ 3 month increase in PFS (14 vs 11 months)
AEs likely will dictate uptake.
Ready for prime time?
Huge progress in the disease by Scott Kopetz.”